Visualization Analysis of Research Status and Hotspots of Treatment for COVID-19 Based on CiteSpace

WANG Yan; XIA Guoguang; CHENG Yang; DAI Li

doi:10.14009/j.issn.1672-2124.2020.08.001

您当前的位置：

首页 >

文章列表页 >

Visualization Analysis of Research Status and Hotspots of Treatment for COVID-19 Based on CiteSpace

更新时间：2022-10-08

- Visualization Analysis of Research Status and Hotspots of Treatment for COVID-19 Based on CiteSpace
- Vol. 20, Issue 8, Pages: 897-901(2020)
- 作者机构：
  
  北京积水潭医院呼吸与危重症医学科
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2020.08.001
  CLC： {G353};R563.1
- Published：2020，
扫描看全文
[1]王艳,夏国光,程洋,戴丽.基于CiteSpace的新型冠状病毒肺炎治疗研究现状及热点的可视化分析[J].中国医院用药评价与分析,2020,20(08):897-901+905.

WANG Yan, XIA Guoguang, CHENG Yang, et al. Visualization Analysis of Research Status and Hotspots of Treatment for COVID-19 Based on CiteSpace. [J]. 20(8):897-901(2020)
[1]王艳,夏国光,程洋,戴丽.基于CiteSpace的新型冠状病毒肺炎治疗研究现状及热点的可视化分析[J].中国医院用药评价与分析,2020,20(08):897-901+905. DOI： 10.14009/j.issn.1672-2124.2020.08.001.

WANG Yan, XIA Guoguang, CHENG Yang, et al. Visualization Analysis of Research Status and Hotspots of Treatment for COVID-19 Based on CiteSpace. [J]. 20(8):897-901(2020) DOI： 10.14009/j.issn.1672-2124.2020.08.001.

摘要

目的:探讨新型冠状病毒肺炎（COVID-19）治疗的研究现状及热点

以期为临床医师的治疗决策及相关科研人员的进一步深入研究提供参考。方法:检索PubMed数据库和Web of Science核心合集数据库

获取COVID-19治疗相关研究文献

检索时限为2019年12月1日至2020年5月23日

采用End Note X9.2软件进行去重。利用Cite Space 5.6.R3软件对作者、国家、机构进行合作网络分析

对关键词进行共现分析

对文献、期刊进行共被引分析。结果:共纳入4 051篇文献。研究结果显示

COVID-19治疗领域的主要核心作者为"LIU LEI""JIANG SHIBO""LIU YINGXIA""YANG YANG""YUAN JING"和"LINDSEY R BADEN";发表文献较多的机构依次为华中科技大学、中国科学院、德黑兰医科大学、首都医科大学、复旦大学和武汉大学等;高频关键词主要有"covid-19""sars-cov-2""antiviral therapy""hydroxychloroquine""chloroquine""immunomodulation""remdesivir""tocilizumab""lopinavir/rironavir""traditional chinese medicine"和"convalescent plasma"等;高被引频次论文中

居前2位的论文分别来自Huang C等（2020年）、Chen N等（2020年）;共被引频次较高的期刊主要有《Lancet》《New England Journal of Medicine》和《Nature》等。结论:各国学者、机构间密切合作

在COVID-19治疗领域的抗病毒药、免疫调节药、中医药3个方面展开深入研究

研究热点主要集中在通过临床试验评估现有的治疗手段如洛匹那韦/利托那韦、瑞德西韦、羟氯喹、氯喹、托西珠单抗以及恢复期血浆等的有效性及安全性

同时以病毒生命周期步骤及机体免疫调节为靶点进行新药研发。

Abstract

OBJECTIVE:To probe into the research status and hotspots of treatment for COVID-19 based on CiteSpace

so as to provide reference for treatment decisions of clinicians and further study of related researchers.METHODS:PubMed and Web of Science were retrieved to collect literature related to treatment for COVID-19.The retrieval time was from Dec.1 st

2019 to May 23 rd

2020.The duplicate literature were removed by using EndNote X9.2.CiteSpace 5.6.R3 software was used to analyze the cooperative network of authors

countries and institutions

cooccurrence analysis of keywords and co-citation analysis of literature and periodicals were performed.RESULTS:Totally4 051 literature were included.The research results showed that the main core authors in the field of COVID-19 treatment were "LIU LEI"

"JIANG SHIBO"

"LIU YINGXIA"

"YANG YANG"

"YUAN JING"and "LINDSEY R BADEN".The institutions with more publications were Huazhong University of Science and Technology

Chinese Academy of Sciences

Tehran University of Medical Sciences

Capital Medical University

Fudan University and Wuhan University.High frequency keywords were " covid-19 "

" sars-cov-2 "

" antiviral therapy "

"hydroxychloroquine"

"chloroquine"

"immunomodulation"

"remdesivir"

"tocilizumab"

"lopinavir/rironavir"

"traditional chinese medicine"and"convalescent plasma".Among the highly cited papers

the top two papers were from Huang C et al.（2020） and Chen N et al.（2020）.The main journals with high total citation frequency were Lancet

New England Journal of Medicine and Nature.CONCLUSIONS:Scholars and institutions from various countries have cooperated closely to conduct in-depth research on three aspects of antiviral drugs

immunomodulatory drugs

and traditional Chinese medicine in the field of COVID-19 treatment.Research hotspots mainly focus on evaluating the effectiveness and safety of treatment such as lopinavir/ritonavir

remdesivir

hydroxychloroquine

chloroquine

tocilizumab and convalescent plasma through clinical trials.Meanwhile

the research and development of new drugs targeted at the life cycle steps of the virus and the immune regulation of the body are in progress.

关键词

新型冠状病毒治疗CiteSpace

Keywords

SARS-CoV-2TreatmentCiteSpace

references

查看原文

Views

281

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Progress of Neutralizing Antibodies Against SARS-CoV-2

Recommendations and Evidence for COVID-19 Vaccine in Patients with Atopic Dermatitis

Research Status and Hotspots of Treatment for Monoclonal Antibody Drugs

Recommendations and Evidence for COVID-19 Vaccine in Patients with Systemic Lupus Erythematosus

Related Author

谭玲

陈露露

谭琳

倪倩

金鹏飞

那一凡

HE Xia

YANG Qianwen

Related Institution

Beijing Hospital

School of Medicine, University of Electronic Science and Technology of China

Dept.of Pharmacy, Sichuan Academy of Medical Sciences ＆ Sichuan Provincial People’s Hospital

School of Medicine/Sichuan Provincial Key Laboratory of Individualized Drug Therapy, University of Electronic Science and Technology of China

Dept.of Clinical Laboratory, Sichuan Academy of Medical Sciences ＆ Sichuan Provincial People’s Hospital

⁰